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Abstract
Systemic lupus erythematosus (SLE) patients express high titers of somatically mutated serum autoantibodies against
nuclear structures including double-stranded DNA. These somatic mutations accumulate codons for basic amino acids in the
immunoglobulin variable regions of both, heavy and light chains, facilitating binding to nucleic acids. The variable (V)
immunoglobulin lambda 8 (IGLV8S1) gene contributes to autoreactive B-cell repertoire of auto-immune patients.
Accumulation of immune complexes of these anti-DNA autoantibodies causes severe systemic inflammation in SLE. The
current treatment of lupus disease is based on immunosuppressive drugs, but the precise role for this therapy remains to be
defined. To evaluate the in vivo effect of combined immunosuppressive treatment on B-lymphocytes repertoire of SLE
patients, we have developed an approach using the IGLV8S1 gene as a marker. The transcription of this gene in treated SLE
patients was increased. However, we observed a trend, in these patients, to conserve complementarity determining regions
(CDRs) and framework regions (FRs) of VV8 polypeptide light chain deduced sequence, from its germline counterpart.
Sequencing IGLV8S1 cDNA of untreated SLE patients, taken as a control for treatment effect, displayed a decreased
frequency of silent somatic mutations (consequently high frequency of replacement mutations) in the VV8 polypeptide chain
deduced sequence. These data suggest that the immunosuppressive drug treatment modulates the positive selection of
somatically mutated VV8 light chain. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The human immunoglobulin lambda light chains
represent about 40% of the functional serum anti-
bodies, indicating the important role played by these
chains in the antibody response [1].
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The lambda variable locus (IGLV) extends about
800 kb on chromosome 22q11.1^11.2 and has been
mapped and fully sequenced by contig methodology,
which has permitted the localization of all the known
V-lambda genes and pseudogenes. We know the po-
sitions of about 70 germline V-lambda sequences,
30^33 of which are functional V-lambda genes dis-
tributed into 11 IGLV gene subgroups (IGLV1^
IGLV11) [2^5].
Southern blot studies with genomic DNA of nor-
mal individuals and patients with auto-immune dis-
eases using a probe speci¢c for the IGLV8 subgroup,
have revealed association between EcoRI-RFLP and
manifestation of systemic lupus erythematosus (SLE)
and RA [6].
An orphan gene belonging to the IGLV8 subgroup
translocated from the major IGLV locus on chromo-
some 22q11.1 to chromosome 8q11.2 was described,
and there is evidence that its expression is associated
with the manifestation of auto-immune diseases [7^
9].
SLE is a disease of unknown etiology character-
ized by in£ammation in many di¡erent organ sys-
tems associated with the production of antibodies
reactive with nuclear (DNA and RNA), cytoplasmic
and cell membrane antigenic determinants [10].
The current treatment of SLE patients is based on
combined immunosuppressive drugs and antimalar-
ials leading to remission of the main clinical features
in these patients [11], but the precise role for this
therapy remains to be de¢ned.
Analysis of immunoglobulin variable region genes
of human hybridomas prepared from auto-immune
disease patients, including SLE, has shown the par-
ticipation of the somatically mutated lambda varia-
ble IGLV2a2 and IGLV8 gene subgroups in patho-
genic autoantibodies [12^14].
To further evaluate the participation of the
IGLV8S1 gene in the peripheral B-cell repertoire of
SLE patients under immunosuppressive treatment,
we have developed a novel approach that provides
a more comprehensive representation of the tran-
scription levels and somatic mutation spectrum of
this gene from several patients than obtained by
the single hybridoma analysis approach.
The expression of the IGLV8S1 gene in the periph-
eral B-lymphocytes of treated SLE patients was in-
creased in relation to normal individuals.
However, in the treated patients, there is a ten-
dency to conserve complementarity determining re-
gions (CDRs) and framework regions (FRs) of VV8
light chain deduced polypeptide sequence from its
germline gene counterpart. We analyzed IGLV8S1
cDNAs of untreated SLE patients, used as control
of treatment e¡ects ¢nding a decreased frequency of
silent somatic mutations in the deduced VV8 poly-
peptide sequence.
These data suggest that the immunosuppressive
treatment used in the SLE patients analyzed down-
regulates the somatically mutated VV8 chain express-
ing B-cell clones.
2. Patients, materials and methods
2.1. Auto-immune disease patients and normal
individuals
We studied samples from 27 SLE patients (22
women and ¢ve men) ful¢lling the criteria of the
American College of Rheumatology for auto-im-
mune diseases [15] who received combined treatment
with prednisone, chloroquine, methotrexate and aza-
thioprine, ¢ve untreated SLE patients (all women)
and samples from 27 normal individuals (22 women
and ¢ve men), all three groups from Ribeira‹o Preto
region, Sa‹o Paulo State, southeastern Brazil.
2.2. IGLV8S1 gene expression measurements
Preparations of total RNA were obtained from
peripheral blood lymphocytes of each SLE patient
or normal individuals using Trizol Reagent accord-
ing to the instructions of Gibco-BRL. The integrity
of the RNA samples was evaluated by Northern blot
using a 33P-radiolabeled oligonucleotide recognizing
28S rRNA as probe (data not shown).
The approach is based ¢rst on generation of
cDNA from total RNA samples using oligo
dT12ÿ18 to prime the reverse transcription reaction
(Ready-to-Go system, Amersham Pharmacia Bio-
tech). The total cDNA samples were dot-blotted on
a nylon membrane (Hybond N+, Amersham Phar-
macia Biotech) using a 96-well Hybri-dot Manifold
apparatus (BRL).
We performed quanti¢cations of dot-blot hybrid-
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izations with a 33P-radiolabeled oligonucleotide
probe speci¢c for the IGLV8S1 FR1 exon region
(5P-CTGAGAACGATGGCTCCTGGG-3P) [16] us-
ing a phosphorimager system (Cyclone, Packard In-
struments, USA) and the OptiQuant (R) software to
measure the hybridization signals.
The values of the IGLV8S1 hybridizations were
compared with hybridizations of each sample of
cDNA with 33P-radiolabeled oligo dA80, which was
used as a probe to estimate the amount of total
cDNA applied to the spots. The results are expressed
as percent of IGLV8S1 cDNA (mRNA) in relation
to the total cDNA.
2.3. Reverse transcription-polymerase chain reaction
(RT-PCR), cloning and DNA sequencing
We performed PCR with total cDNA (reverse
transcription followed by PCR, RT-PCR) from
SLE or normal individuals using one pair of oligo-
nucleotides which ampli¢es a 249 base pair (bp)
product speci¢c for the IGLV8S1 gene exon. The
primers used were: the 21-mer 5P-GGTGACCCAG-
GAGCCATCGTT-3P forward, positions 179^199
covering a portion from the CDR1 region; and the
21-mer 5P-GGCCCAGGCAGATGATGAATC-3P
reverse, positions 408^428 covering a portion from
the FR3.
The PCR conditions were as follows: 100 ng of
total cDNA, 100 ng of each primer, 200 WM of
each dNTP, and 2.5 U of Taq polymerase (Amer-
sham-Pharmacia Biotech) in 100 Wl of 1UPCR bu¡er
supplied with the enzyme. The PCR pro¢le was:
94‡C for 3 min, 60‡C for 10 min (one cycle), 72‡C
for 2 min, 94‡C for 1.5 min, 60‡C for 2 min (30
cycles), 72‡C for 10 min, and 10‡C for 5 min (one
cycle). The PCR products were cloned in pUC-18
using the Ready-to-Go cloning kit (Amersham-Phar-
macia Biotech).
The sequencing of the cloned RT-PCR products
using Thermo Sequenase Cy 5.5 and a Seq 4U4 Au-
tomatic DNA Sequencer (Amersham Pharmacia Bio-
tech) provided a spectrum of somatic mutations in
FRs and CDRs of the IGLV8S1 cDNA (mRNA).
The sequences were compared using the IMGT/V-
QUEST software from IMGT Database (http://
imgt.cines.fr:8104) and submitted to GenBank
(www.ncbi.nlm.nih.gov/).
3. Results and discussion
As seen in Fig. 1, the transcription level of the
IGLV8S1 gene was signi¢cantly increased in periph-
eral lymphocytes of SLE patients than of normal
individuals.
Sequence comparisons using the IMGT/V-QUEST
software revealed that SLE patients receiving immu-
nosuppressive treatment trend to express FRs and
CDRs as coded by the IGLV8S1 germline gene. In
normal individuals, the extent of silent mutations in
these regions is lower, diversifying the (deduced) light
chain sequences in the repertoire. We evaluated the
extent of somatic mutations in the IGLV8S1 mRNA
(cDNA) from untreated SLE patients as a control
for treatment e¡ects and a decreased frequency of
silent somatic mutations (consequently high fre-
quency of replacement mutations) was seen (Fig. 2).
The total R/S ratio in the CDR regions of
IGLV8S1 mRNA (cDNA) from treated SLE patients
was lower (R/STÿSLE = 2.5) than in normal individu-
als (R/SN = 3.5) or than in untreated SLE patients
(R/SUTÿSLE = 4.4) (Tables 1^3).
This pattern suggests that in immunosuppressed
SLE patients with controlled disease, there is a re-
duced positive selection of somatically mutated VV8
polypeptide chain expressing B-cell clones.
The mechanisms responsible for the initiation and
maintenance of pathogenic autoantibody production
are still poorly understood. Anti-DNA antibodies
produced by autoreactive B-cells can also be found
in the normal repertoire among the so called ‘natural
autoantibodies’ [17,18].
In contrast to the IgG bearing somatically mutated
VV8 chain anti-double-stranded DNA antibodies
which display high avidity in SLE [12], the natural
Fig. 1. Expression level of the IGLV8S1 mRNA (as measured
by the relative cDNA amount) in peripheral B-lymphocytes of
normal individuals or SLE patients (SLE). The values of SLE
were statistically di¡erent to the normal as evaluated by the
Student’s t-test (K= 0.05). Values are expressed in DLU/mm2
(digital light units as displayed by the phosphorimager system).
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anti-DNA antibodies are of lower a⁄nity and cross-
react with several autologous as well as foreign anti-
gens [18,19].
Our ¢ndings revealed that the IGLV8S1 mRNA
expressed by peripheral B-cells of treated SLE pa-
tients conserve the germline sequence.
The evaluation of gene expression level and cDNA
sequencing proved to be a powerful method to mea-
sure the in vivo e¡ect of immunosuppressive treat-
ment on B-cells using the IGLV8S1 gene as a
marker.
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